WeVote
Log In

Bill

Bill

S 760

Kids’ Access to Primary Care Act of 2025

119th Congress Introduced by Richard Blumenthal and 5 co-sponsors

Bill S 760 mandates health insurance coverage for epinephrine auto-injectors, ensuring individuals with severe allergies can access life-saving treatment without financial barriers.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 760

Summary of Bill S 760: Insurance Coverage for Epinephrine Auto-Injectors

Bill Overview

  • Bill Number: S 760
  • Title: Relates to requiring insurance coverage for epinephrine auto-injectors
  • Status: Signed into law (Chap. 81)
  • Introduced: January 8, 2025

Purpose and Intent

The primary purpose of Bill S 760 is to mandate that health insurance plans provide coverage for epinephrine auto-injectors. This legislation aims to improve access to life-saving medication for individuals at risk of severe allergic reactions (anaphylaxis), thereby enhancing public health and safety.

Key Provisions

  • Insurance Coverage Requirement: The bill requires all health insurance policies to cover epinephrine auto-injectors without imposing excessive cost-sharing measures, such as high deductibles or copayments.
  • Accessibility: The legislation ensures that individuals with allergies can obtain these critical devices without financial barriers, promoting timely treatment in emergency situations.

Affected Parties

  • Individuals with Allergies: The primary beneficiaries of this bill are individuals who suffer from severe allergies and require epinephrine auto-injectors for emergency treatment.
  • Health Insurance Providers: Insurance companies will need to adjust their policies to comply with the new coverage requirements.
  • Healthcare Providers: Physicians and healthcare professionals will have clearer guidelines regarding the prescription and coverage of epinephrine auto-injectors.

Legislative Timeline

  • January 8, 2025: Bill introduced and referred to rules.
  • February 4, 2025: Passed in the Senate and delivered to the Assembly.
  • February 5, 2025: Substituted for companion bill A 2443, passed in the Assembly, and returned to the Senate.
  • February 12, 2025: Delivered to the Governor.
  • February 14, 2025: Signed into law as Chap. 81.

Conclusion

Bill S 760 represents a significant step towards ensuring that individuals at risk of anaphylaxis have access to necessary medical treatment without financial hardship. By mandating insurance coverage for epinephrine auto-injectors, the legislation aims to save lives and improve health outcomes for those affected by severe allergies.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.